Compare CZWI & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZWI | TARA |
|---|---|---|
| Founded | 1938 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.1M | 165.5M |
| IPO Year | N/A | N/A |
| Metric | CZWI | TARA |
|---|---|---|
| Price | $17.96 | $5.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $20.40 |
| AVG Volume (30 Days) | 28.4K | ★ 1.1M |
| Earning Date | 01-26-2026 | 11-10-2025 |
| Dividend Yield | ★ 2.01% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $58,987,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.29 | N/A |
| P/E Ratio | $13.94 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.69 | $2.77 |
| 52 Week High | $18.74 | $7.82 |
| Indicator | CZWI | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 55.88 | 46.76 |
| Support Level | $17.98 | $5.26 |
| Resistance Level | $18.49 | $6.37 |
| Average True Range (ATR) | 0.29 | 0.31 |
| MACD | -0.09 | -0.07 |
| Stochastic Oscillator | 16.18 | 38.06 |
Citizens Community Bancorp Inc is a bank holding company that offers traditional community banking services to businesses, Agricultural operators, and consumers, including one-to-four-family residential mortgages. it also offers a variety of loan products including commercial real estate loans, commercial and industrial (C&I) loans, agricultural real estate loans, agricultural operating loans, residential mortgages, home equity lines-of-credit, and consumer loans and offers deposit products through its branches, including demand deposits, various savings and money-market accounts and certificates of deposit. The company's sources of funds are deposits; amortization, prepayments, and maturities of outstanding loans; other short- term investments; and funds provided from operations.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).